SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
March 28, 2005
HALOZYME THERAPEUTICS, INC.
|(State or other jurisdiction
|11588 Sorrento Valley Road, Suite 17, San Diego, California||92121|
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (858) 794-8889
|(Former name or former address, if changed since last report.)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|Item 8.01 Other Events.|
|Item 9.01 Financial Statements and Exhibits.|
Item 8.01 Other Events.
On March 28, 2005, Halozyme Therapeutics, Inc. announced that it filed a new drug application (NDA) with the U.S. Food and Drug Administration for Enhanze SC. The press release announcing the filing of the NDA is attached hereto as Exhibit 99.1 and is incorporated by reference.
Item 9.01 Financial Statements and Exhibits.
|Press Release dated March 28, 2005.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Halozyme Therapeutics, Inc.
|March 28, 2005||By:||/s/ David A. Ramsay|
|David A. Ramsay|
|Secretary and Chief Financial Officer|